BionimeTPE:4737 -2.80%65 Market Cap is NT$4,297 Mil as of Jun. 30, 2026. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$58.96 (Fairly Valued). The stock has 7 warning signs investors should review. Among 867 Medical Devices & Instruments companies, Bionime ranks better than 52.13% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Bionime's share price for the quarter that ended in Dec. 2025 was NT$58.925216. Bionime's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 68 Mil. Therefore, Bionime's market cap for the quarter that ended in Dec. 2025 was NT$4,003 Mil.
Bionime's quarterly market cap
declined
from Jun. 2025 (NT$4,429 Mil) to Sep. 2025 (NT$4,246 Mil) and
declined
from Sep. 2025 (NT$4,246 Mil) to Dec. 2025 (NT$4,003 Mil).
Bionime's annual market cap
declined
from Dec. 2023 (NT$4,549 Mil) to Dec. 2024 (NT$3,949 Mil) but then
increased
from Dec. 2024 (NT$3,949 Mil) to Dec. 2025 (NT$4,003 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Bionime's Enterprise Value for Today is NT$6,882 Mil.
Bionime (TPE:4737) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Bionime Market Cap Related Terms
Bionime Market Cap Historical Data
* Premium members only.
The historical data trend for Bionime's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:4737 vs ISRG, BDX, MDLN: Market Cap Comparison
For the Medical Instruments & Supplies subindustry, Bionime's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionime Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionime's Market Cap distribution charts can be found below:
* The bar in red indicates where Bionime's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Bionime's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionime (TPE:4737) has a Market Cap of NT$4,297 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bionime and its competitors. According to the industry distribution chart, Bionime ranks #415 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 47.9%.
Is Bionime's Market Cap too high?
Bionime's current Market Cap is NT$4,297 Mil. Based on the distribution chart, Bionime ranks #415 out of 867 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Market Cap compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bionime ranks #415 out of 867 companies for Market Cap. This puts Bionime in the upper half of its industry. The industry median Market Cap is 120.18. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 120.18, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Bionime and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 120.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionime's current Market Cap is NT$4,297 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.96, compared to a current price of NT$55.60 — trading 5.7% below its estimated fair value. The current Market Cap is NT$4,297 Mil. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Bionime (TPE:4737), the current Market Cap is NT$4,297 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionime (TPE:4737) Overvalued in 2026?
Based on GuruFocus' analysis, Bionime stock appears to be undervalued.
The current stock price of NT$55.60 is trading 5.7% below its estimated GF Value™ of NT$58.96.
GuruFocus considers Bionime to be Fairly Valued.
Key valuation signals for TPE:4737:
Market Cap: NT$4,297 Mil
GF Value™: NT$58.96 vs. price of NT$55.60 (5.7% below fair value)
No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score
Get the complete analysis for TPE:4737
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4737 has been successfully added to your 
